CliffBio
small molecule

LAMIVUDINE AND ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameLAMIVUDINE AND ZIDOVUDINE
Active ingredientLAMIVUDINE; ZIDOVUDINE
Strength150MG;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LAMIVUDINE AND ZIDOVUDINE patent cliff — loss of exclusivity — | CliffBio